Skip to content
OpenCapital
Get started

BridgeBio Pharma BBIO License and services revenue — Revenue

Other product segments

Cost of license, services, and royalty revenue
$10.3M—

Similar metrics at other companies

Insmed logo
INSMLicense and Service — Revenue from Contract with Customer, Including Assessed Tax
$1B—
Cytokinetics logo
CYTKLicense And Service — Revenue
$1.92M+502%
Ionis Pharmaceuticals logo
IONSLicense — Revenue
$25M+108%
Neurocrine Biosciences logo
NBIXLicense — Revenue
$15M—
Roivant Sciences logo
ROIVLicense Milestone And Other Revenue — Revenue
$36.77M+640%
Exelixis logo
EXELLicense revenues — Total revenues
$56.95M+34.1%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity2×—
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's license and services revenue — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's license and services revenue — revenue?
BridgeBio Pharma (BBIO) reported license and services revenue — revenue of $4.42M in Q1 2026.
How has BridgeBio Pharma's license and services revenue — revenue changed year-over-year?
BridgeBio Pharma's license and services revenue — revenue decreased by 94.5% year-over-year, from $79.69M to $4.42M.
What is the long-term trend for BridgeBio Pharma's license and services revenue — revenue?
Over 3 years (2021 to 2025), BridgeBio Pharma's license and services revenue — revenue has grown at a 22.7% compound annual growth rate (CAGR), from $65.92M to $121.88M.
What does license and services revenue — revenue mean?
Total income earned from licensing agreements and related service contracts.
How do you interpret license and services revenue — revenue?
An increase indicates successful commercialization or partnership activity, while a decrease may signal expiring licenses or delays in milestone achievements.
How does license and services revenue — revenue compare across companies?
Common in biotech and pharmaceutical companies with out-licensing business models; peers often report this as 'Collaboration Revenue' or 'License Revenue'.